Last $8.97 USD
Change Today -0.06 / -0.66%
Volume 151.0K
POZN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

pozen inc (POZN) Snapshot

Open
$9.05
Previous Close
$9.03
Day High
$9.09
Day Low
$8.96
52 Week High
04/25/14 - $9.73
52 Week Low
07/31/14 - $5.96
Market Cap
287.7M
Average Volume 10 Days
306.5K
EPS TTM
$0.34
Shares Outstanding
32.1M
EX-Date
12/31/13
P/E TM
26.7x
Dividend
--
Dividend Yield
19.51%
Current Stock Chart for POZEN INC (POZN)

Related News

No related news articles were found.

pozen inc (POZN) Related Businessweek News

No Related Businessweek News Found

pozen inc (POZN) Details

POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its primary PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company’s products also include Treximet for acute treatment of migraine attacks with or without aura in adults; and VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and Sanofi US for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

16 Employees
Last Reported Date: 03/6/14
Founded in 1996

pozen inc (POZN) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $591.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $353.1K
Chief Medical Officer
Total Annual Compensation: $372.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $339.8K
Compensation as of Fiscal Year 2013.

pozen inc (POZN) Key Developments

POZEN Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

POZEN Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $7,539,741 compared to $2,583,000 a year ago. Net income attributable to common stockholders was $6,752,169 or $0.20 per diluted share compared to loss of $4,767,193 or $0.16 per basic and diluted share a year ago. The 2014 revenue is comprised of royalty from sales of VIMOVO of $5.5 million and $2 million amortization of the upfront payment from Sanofi US license, whereas the prior year revenue included $1.6 million of VIMOVO royalty and $1 million of amortization of the upfront payment on the Sanofi US license. For the nine months, the company reported total revenue of $22,507,723 compared to $5,649,000 a year ago. Net income attributable to common stockholders was $12,656,318 or $0.39 per diluted share compared to loss of $14,533,121 or $0.48 per diluted share a year ago. For 2014, the company continue to expect to be profitable and to generate positive cash flow.

POZEN Inc. to Report Q3, 2014 Results on Nov 06, 2014

POZEN Inc. announced that they will report Q3, 2014 results at 11:00 AM, US Eastern Standard Time on Nov 06, 2014

POZEN Inc., Q3 2014 Earnings Call, Nov 06, 2014

POZEN Inc., Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POZN:US $8.97 USD -0.06

POZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,676 GBp -35.00
Endo International PLC $72.22 USD -0.28
GlaxoSmithKline PLC 1,470 GBp -0.50
Merck & Co Inc $59.34 USD +0.09
Sunesis Pharmaceuticals Inc $2.22 USD -0.04
View Industry Companies
 

Industry Analysis

POZN

Industry Average

Valuation POZN Industry Range
Price/Earnings 27.7x
Price/Sales 10.5x
Price/Book 7.6x
Price/Cash Flow 27.6x
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POZEN INC, please visit www.pozen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.